Into the Unknown: Practical Remdesivir Restriction in the Era of Widespread SARS-CoV-2 Seropositivity
Restriction of remdesivir use in immunocompetent patients was not associated with an increased risk of mortality. Remdesivir use was associated with an unexpected increased risk of ICU admission and MV use within the post-intervention group, likely explained by the higher-risk patient population that received remdesivir. Prospective studies are needed to definitively determine if highly immunocompetent patients benefit from remdesivir.
Authors
- S.K. Gustafson
- Stefan Collinet‐Adler
- Brent Footer (ORCID: https://orcid.org/0000-0002-8585-1722)
- Zachary Nelson (ORCID: https://orcid.org/0000-0002-2759-801X)
- Alyssa Christensen (ORCID: https://orcid.org/0000-0002-1497-3116)
- Laura Grangaard Johnson
- Nicole K. Trower
- Elizabeth B. Hirsch (ORCID: https://orcid.org/0000-0002-0462-0421)
- Rachel Stoecker
- Maxx Enzmann (ORCID: https://orcid.org/0000-0002-3927-0142)
- Sarah Rebecca Peglow
- Ethan Ryberg
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Minnesota (US)
- University of Minnesota System (US)
- Park Nicollet Health Services (US)
- HealthPartners (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1093/cid/ciaf217
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00